Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Blood (2018) 132 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2018-99-113284

Published: 2018

Journal Articles

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Blood (2018) 132 (Supplement 1): 124.

https://doi.org/10.1182/blood-2018-99-112899

Published: 2018

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

Esther Drent, MSc, Maria Themeli, MD PhD, Renée Poels, Niels W.C.J. van de Donk, MD PhD, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD

Blood (2016) 128 (22): 2170.

https://doi.org/10.1182/blood.V128.22.2170.2170

Published: 2016

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

Bone Marrow Neutralizes Human Regulatory T-Cells to Permit Graft-Versus-Tumor Immunity In Humanized Mice

Teun Guichelaar, PhD, Henk Rozemuller, PhD, Maarten Emmelot, Bianka Martini, Gert Storm, Henk M Lokhorst, MD, PhD, Anton Martens, PhD, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 1017.

https://doi.org/10.1182/blood.V116.21.1017.1017

Published: 2010

Journal Articles

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2010) 116 (21): 3058.

https://doi.org/10.1182/blood.V116.21.3058.3058

Published: 2010

Journal Articles

Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.

Robbert M Spaapen, Kelly van den Oudenalder, Maureen van Elk, Tineke Aarts, Teun Guichelaar, Richard WJ Groen, Andries C Bloem, Gert Storm, Anton C Martens, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD

Blood (2009) 114 (22): 1333.

https://doi.org/10.1182/blood.V114.22.1333.1333

Published: 2009

Journal Articles

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Evelien Kneppers, Monique C. Minnema, MD, PhD, Tineke Aarts, Maarten E. Emmelot, Ineke Slaper-Cortenbach, PhD, Kasper Westinga, Tuna Mutis, MD, PhD, Henk M. Lokhorst, MD, PhD

Blood (2009) 114 (22): 2875.

https://doi.org/10.1182/blood.V114.22.2875.2875

Published: 2009

Journal Articles

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myeloid Leukemia Patients Older Than 40 Years.

Cynthia Huisman, MD, PhD, Ellen Meijer, MD, PhD, Eefke J. Petersen, MD, PhD, Henk M. Lokhorst, MD, PhD, Leo F. Verdonck, MD, PhD

Blood (2007) 110 (11): 5074.

https://doi.org/10.1182/blood.V110.11.5074.5074

Published: 2007

Journal Articles

A Single Nucleotide Polymorphism in CD19 Defines a Novel Target for Immunotherapy of B Cell Malignancies with CD4 + Cytotoxic T Cells.

Robbert M. Spaapen, MSc, Henk M. Lokhorst, MD PhD, Kelly van den Oudenalder, Brith Otterud, PhD, Harry Dolstra, PhD, Mark Leppert, PhD, Monique C. Minnema, MD PhD, Andries C. Bloem, PhD, Tuna Mutis, MD PhD

Blood (2007) 110 (11): 1798.

https://doi.org/10.1182/blood.V110.11.1798.1798

Published: 2007

Journal Articles

An Observational Post Authorization Study on the Use of Bortezomib in Multiple Myeloma Patients in The Netherlands: Results of an Interim Analysis.

Douwe H. Biesma, MD, PhD, Henk M. Lokhorst, MD PhD, Klaas van der Hem, MD PhD, Cees van der Heul, MD PhD

Blood (2007) 110 (11): 4808.

https://doi.org/10.1182/blood.V110.11.4808.4808

Published: 2007

Journal Articles

A Novel In Vivo Animal Model for Human Multiple Myeloma Based on Bioluminescence Imaging of Tumor Cell Growth.

Anton C. Martens, PhD, Henk Rozemuller, PhD, Ellen van der Spek, MD, Lijnie Bogers-Boer, Niels van de Donk, MD, PhD, Andries Bloem, PhD, Henk M. Lokhorst, MD, PhD

Blood (2005) 106 (11): 3452.

https://doi.org/10.1182/blood.V106.11.3452.3452

Published: 2005

Journal Articles

A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.

Henk M. Lokhorst, MD, PhD, Niels van de Donk, MD, PhD, Ellen van de Spek, MD, Okke de Weerdt, MD, Rene van de Griend, MD, PhD, Shulamiet Wittebol, MD, Leo F. Verdonck, MD, PhD, Andries C. Bloem, MD, PhD

Blood (2004) 104 (11): 3458.

https://doi.org/10.1182/blood.V104.11.3458.3458

Published: 2004

NARROW

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Bone Marrow Neutralizes Human Regulatory T-Cells to Permit Graft-Versus-Tumor Immunity In Humanized Mice

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myeloid Leukemia Patients Older Than 40 Years.

A Single Nucleotide Polymorphism in CD19 Defines a Novel Target for Immunotherapy of B Cell Malignancies with CD4 + Cytotoxic T Cells.

An Observational Post Authorization Study on the Use of Bortezomib in Multiple Myeloma Patients in The Netherlands: Results of an Interim Analysis.

A Novel In Vivo Animal Model for Human Multiple Myeloma Based on Bioluminescence Imaging of Tumor Cell Growth.

A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only